ArticleInfection and immunity1994
Construction and characterization of attenuated delta aroA delta virG Shigella flexneri 2a strain CVD 1203, a prototype live oral vaccine.
Article in Infection and immunity, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Safety, immunogenicity, and transmissibility in humans of CVD 1203, a live oral Shigella flexneri 2a vaccine candidate attenuated by deletions in aroA and virG.Infection and immunity · 1996Trial
- EPSP Synthase-Depleted Cells Are Aromatic Amino Acid Auxotrophs in Mycobacterium smegmatis.Microbiology spectrum · 2021Article
- Characterization of a multicomponent live, attenuated Shigella flexneri vaccine.Pathogens and disease · 2016Article
- Analysis of the proteome of intracellular Shigella flexneri reveals pathways important for intracellular growth.Infection and immunity · 2013Article
- Serological cross-reaction between O-antigens of Shigella dysenteriae type 4 and an environmental Escherichia albertii isolate.Current microbiology · 2013Article
- Systematic annotation and analysis of "virmugens"-virulence factors whose mutants can be used as live attenuated vaccines.Vaccine · 2013Article
- Deletion of internal structured repeats increases the stability of a leucine-rich repeat protein, YopM.Biophysical chemistry · 2011Article
- Article
- Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road.Nature reviews. Microbiology · 2007Review
- Enteric pathogens as vaccine vectors for foreign antigen delivery.Infection and immunity · 2004Review
- Phenotypic and genotypic characterization of serologically atypical strains of Shigella flexneri type 4 isolated in Dhaka, Bangladesh.Journal of clinical microbiology · 2002Article
- Vaccination with a Shigella DNA vaccine vector induces antigen-specific CD8(+) T cells and antiviral protective immunity.Journal of virology · 2001Article
- Shigella infection in a SCID mouse-human intestinal xenograft model: role for neutrophils in containing bacterial dissemination in human intestine.Infection and immunity · 2001Article
- Parameters underlying successful protection with live attenuated mutants in experimental shigellosis.Infection and immunity · 2001Article
- Isolation and characterization of a Shigella flexneri invasin complex subunit vaccine.Infection and immunity · 2000Article
- Attenuated Shigella flexneri 2a vaccine strain CVD 1204 expressing colonization factor antigen I and mutant heat-labile enterotoxin of enterotoxigenic Escherichia coli.Infection and immunity · 2000Article
- Constitutive expression of the Vi polysaccharide capsular antigen in attenuated Salmonella enterica serovar typhi oral vaccine strain CVD 909.Infection and immunity · 2000Article
- Shigella flexneri 2a strain CVD 1207, with specific deletions in virG, sen, set, and guaBA, is highly attenuated in humans.Infection and immunity · 2000Article
- Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602.Infection and immunity · 1999Article
- Strategy for cross-protection among Shigella flexneri serotypes.Infection and immunity · 1999Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We engineered an oral Shigella vaccine prototype that can invade intestinal epithelial cells but cannot undergo extensive intracellular replication or extend to adjacent epithelial cells. Strain CVD 1203, derived from wild-type Shigella flexneri 2a by introducing deletions in chromosomal aroA and invasion plasmid virG, was highly attenuated in the Sereny test. Two 10(9)-CFU orogastric doses (2 weeks apart) stimulated production of secretory immunoglobulin A antibodies to S. flexneri 2a and protected against conjunctival sac challenge with virulent S. flexneri 2a.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.